{"DataElement":{"publicId":"3915162","version":"1","preferredName":"Nasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"Stage group determined from information on the tumor (T), regional node (N) and metastases (M) and by grouping cases with similar prognosis for nasopharyngeal cancer.","longName":"3914942v1.0:3914924v1.0","context":"NCIP","contextVersion":"1","DataElementConcept":{"publicId":"3914942","version":"1","preferredName":"Nasopharynx Tumor Stage Grouping","preferredDefinition":"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages._A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.","longName":"2452490v1.0:2230143v1.0","context":"NCI Standards","contextVersion":"1","ObjectClass":{"publicId":"2452490","version":"1","preferredName":"Nasopharynx Neoplasm","preferredDefinition":"The nasal part of the pharynx, lying above the level of the soft palate.:(NEE-o-PLAY-zha) Abnormal and uncontrolled cell growth.","longName":"C12423:C3262","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharynx","conceptCode":"C12423","definition":"The part of the pharynx in the back of the throat, at and above the soft palate. The nasopharynx is continuous with the nasal passages.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm","conceptCode":"C3262","definition":"A benign or malignant tissue growth resulting from uncontrolled cell proliferation. Benign neoplastic cells resemble normal cells without exhibiting significant cytologic atypia, while malignant cells exhibit overt signs such as dysplastic features, atypical mitotic figures, necrosis, nuclear pleomorphism, and anaplasia. Representative examples of benign neoplasms include papillomas, cystadenomas, and lipomas; malignant neoplasms include carcinomas, sarcomas, lymphomas, and leukemias.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"0D51E8D8-66FC-387C-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2006-02-23","endDate":null,"createdBy":"ALAIS","dateCreated":"2006-02-23","modifiedBy":"ONEDATA","dateModified":"2006-02-23","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2230143","version":"1","preferredName":"Stage Grouping","preferredDefinition":"Stage Grouping; an assessment based on the combined evaluation of the patient's T stage, M stage, and N stage. (caDSR)","longName":"C38027","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F752037A-4CC2-36A8-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-18","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-05-18","modifiedBy":"ONEDATA","dateModified":"2005-05-18","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E7ECED27-38E6-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"TAYLORT","dateModified":"2020-01-08","changeDescription":"1/8/20 tmt added Registration Status.; 1/8/20 tmt transferred ownership from NCIP to NCI Standards. Created per RTOG request for CRF standard harmonization. mc 10/4/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3914924","version":"1","preferredName":"Nasopharyngeal Cancer American Joint Committee on Cancer (AJCC) Edition 7 Group Stage","preferredDefinition":"A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 7th edition._An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"3914924v1.0","context":"NCIP","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":"1","maxLength":"13","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Stage unknown","valueDescription":"Stage Unknown","ValueMeaning":{"publicId":"3357508","version":"1","preferredName":"Stage Unknown","longName":"3357508","preferredDefinition":"A finding indicating that the extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage Unknown","conceptCode":"C92207","definition":"The extent of organ/tissue involvement by a malignant neoplasm is not reported or not assessed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B6D76279-6263-2CA8-E040-BB89AD434A54","latestVersionIndicator":"Yes","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2012-01-18","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-379A-914F-E040-BB89AD436D0B","beginDate":"2012-01-18","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"IVC","valueDescription":"Stage IVC Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914928","version":"1","preferredName":"Stage IVC Nasopharyngeal Carcinoma","longName":"3914928","preferredDefinition":"Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVC Nasopharyngeal Carcinoma AJCC v7","conceptCode":"C5995","definition":"Stage IVC includes: Any T, Any N, M1. M1: Distant metastasis. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-37CD-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-37E6-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"IVA","valueDescription":"Stage IVA Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914930","version":"1","preferredName":"Stage IVA Nasopharyngeal Carcinoma","longName":"3914930","preferredDefinition":"Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVA Nasopharyngeal Carcinoma AJCC v7","conceptCode":"C5997","definition":"Stage IVA includes: (T4, N0, M0); (T4, N1, M0); (T4, N2, M0). T4: Nasopharyngeal cancer with intracranial extension and/or involvement of cranial nerves, hypopharynx, orbit, or with extension to the infratemporal fossa/masticator space.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-37F3-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-380C-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"IVB","valueDescription":"Stage IVB Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914932","version":"1","preferredName":"Stage IVB Nasopharyngeal Carcinoma","longName":"3914932","preferredDefinition":"Stage IVB includes: Any T, N3, M0.  N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage IVB Nasopharyngeal Carcinoma AJCC v7","conceptCode":"C5996","definition":"Stage IVB includes: Any T, N3, M0.  N3: Nasopharyngeal cancer with metastasis in a lymph node (s) more than 6 cm in greatest dimension and/or to supraclavicular fossa.  Supraclavicular zone or fossa is relevant to the staging of nasopharyngeal carcinoma and is the triangular region originally described by Ho.  It is defined by three points: (1) the superior margin of the sternal end of the clavicle, (2) the superior margin of the lateral end of the clavicle, (3) the point where the neck meets the shoulder.  This would include caudal portions of levels IV and VB.  All cases with lymph nodes (whole or part) in the fossa are considered N3b.  M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-3819-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-3832-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"II","valueDescription":"Stage II Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914934","version":"1","preferredName":"Stage II Nasopharyngeal Carcinoma","longName":"3914934","preferredDefinition":"Stage II includes: (T1, N1, M0); (T2, N0, M0); (T2, N1, M0).  T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage II Nasopharyngeal Carcinoma AJCC v7","conceptCode":"C88982","definition":"Stage II includes: (T1, N1, M0); (T2, N0, M0); (T2, N1, M0).  T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-383F-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-3858-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"0","valueDescription":"Stage 0 Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914936","version":"1","preferredName":"Stage 0 Nasopharyngeal Carcinoma","longName":"3914936","preferredDefinition":"Abnormal cells are found in the lining of the nasopharynx (the upper part of the throat behind the nose). These abnormal cells may become cancer and spread into nearby normal tissue.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage 0 Nasopharyngeal Carcinoma AJCC v6, v7, and v8","conceptCode":"C9099","definition":"Stage 0 includes: Tis, N0, M0.  Tis: Carcinoma in situ. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 6th, 7th, and 8th eds.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-3865-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-387E-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"I","valueDescription":"Stage I Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914938","version":"1","preferredName":"Stage I Nasopharyngeal Carcinoma","longName":"3914938","preferredDefinition":"Stage I includes: T1, N0, M0. T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage I Nasopharyngeal Carcinoma AJCC v7","conceptCode":"C88981","definition":"Stage I includes: T1, N0, M0. T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. N0: No regional lymph node metastasis.  M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-388B-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-38A4-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"},{"value":"III","valueDescription":"Stage III Nasopharyngeal Carcinoma","ValueMeaning":{"publicId":"3914940","version":"1","preferredName":"Stage III Nasopharyngeal Carcinoma","longName":"3914940","preferredDefinition":"Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  T3: Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Stage III Nasopharyngeal Carcinoma AJCC v7","conceptCode":"C88983","definition":"Stage III includes: (T1, N2, M0); (T2, N2, M0); (T3, N0, M0); (T3, N1, M0); (T3, N2, M0). T1: Nasopharyngeal cancer with tumor confined to the nasopharynx, or tumor extending to oropharynx and/or nasal cavity without parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor. T2: Nasopharyngeal cancer with parapharyngeal extension.  Parapharyngeal extension denotes posterolateral infiltration of tumor.  T3: Nasopharyngeal cancer with tumor involving bony structures of skull base and/or paranasal sinuses.  N0: No regional lymph node metastasis. N1: Nasopharyngeal cancer with unilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa, and/or unilateral or bilateral, retropharyngeal lymph nodes, 6 cm or less in greatest dimension.  Midline nodes are considered ipsilateral nodes.  N2: Nasopharyngeal cancer with bilateral metastasis in cervical lymph node(s), 6 cm or less in greatest dimension, above the supraclavicular fossa.  Midline nodes are considered ipsilateral nodes. M0: No distant metastasis. (AJCC 7th ed.)","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-38B1-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E7ECED27-38CA-914F-E040-BB89AD436D0B","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008537","version":"1","preferredName":"Diagnosis","preferredDefinition":"the process of identifying a disease by the signs and symptoms (NCI Glossary).","longName":"DX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B205508C-8324-69B0-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-17","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-17","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3914923","version":"1","preferredName":"Nasopharyngeal Carcinoma by AJCC v7 Stage Stage Grouping Stage","preferredDefinition":"A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 7th edition.:An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C91244:C38027:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Nasopharyngeal Carcinoma by AJCC v7 Stage","conceptCode":"C91244","definition":"A term that refers to the staging of nasopharyngeal carcinoma according to the American Joint Committee on Cancer, 7th edition.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Stage Grouping","conceptCode":"C38027","definition":"An assessment based on the combined evaluation of the patient's T stage, M stage, and N stage, as well as prognostic parameters for specific cancers.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-3771-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"ONEDATA","dateModified":"2013-10-04","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E7ECED27-3782-914F-E040-BB89AD436D0B","latestVersionIndicator":"Yes","beginDate":"2013-10-04","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-04","modifiedBy":"COOPERM","dateModified":"2015-08-26","changeDescription":"Created per RTOG request for CRF standard harmonization. mc 10/4/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2192345","version":"1","longName":"Data Standards","context":"NCIP","ClassificationSchemeItems":[{"publicId":"2859963","version":"1","longName":"Standard CRFs","context":"NCIP"},{"publicId":"3434437","version":"1","longName":"Staging/Extent of Disease (by Disease)","context":"NCIP"},{"publicId":"3914688","version":"1","longName":"Nasopharyngeal","context":"NCIP"}]},{"publicId":"5574838","version":"1","longName":"Staging/Extent of Disease","context":"NCI Standards","ClassificationSchemeItems":[{"publicId":"10000596","version":"1","longName":"AJCC Edition 7","context":"NCI Standards"},{"publicId":"10000587","version":"1","longName":"Nasopharyngeal","context":"NCI Standards"}]}],"AlternateNames":[{"name":"NASOPHAR_AJCC_DISEASE_STG","type":"OID, RTOG","context":"NCIP"},{"name":"COG","type":"USED_BY","context":"COG"},{"name":"NASOPHAR_AJCC_DISEASE_STG","type":"COG GDE Short Name","context":"COG"}],"ReferenceDocuments":[{"name":"Disease Stage","type":"Preferred Question Text","description":"Disease Stage","url":null,"context":"NCIP"}],"origin":"AJCC Based:Staging Criteria Based on American Joint Committee on Cancer System","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"E828BFA2-B9C7-1538-E040-BB89AD43689A","latestVersionIndicator":"Yes","beginDate":"2013-10-07","endDate":null,"createdBy":"COOPERM","dateCreated":"2013-10-07","modifiedBy":"TAYLORT","dateModified":"2017-04-19","changeDescription":"Created per request by RTOG for CRF Harmonization. mc 10/6/13","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}